Ruxolitinib, ATP-competitive JAK1/2 inhibitor (ab141356)
Key features and details
- Potent, selective ATP-competitive JAK1/2 inhibitor
- CAS Number: 941678-49-5
- Purity: > 99%
Soluble in DMSO to 16 mM and in ethanol to 32 mM
- Form / State: Solid
- Source: Synthetic
Overview
-
Product name
Ruxolitinib, ATP-competitive JAK1/2 inhibitor -
Description
Potent, selective ATP-competitive JAK1/2 inhibitor -
Alternative names
- (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
- INCA24
- INCB 018424
-
Biological description
Potent, selective ATP-competitive Janus-associated kinase 1 and 2 inhibitor (IC50 values of 3.3, 2.8 and 428 nM for JAK1, JAK2 and JAK3 respectively in vitro). Inhibits IL-6 signaling (IC50 = 281nM). Orally bioavailable.
-
Purity
> 99% -
CAS Number
941678-49-5 -
Chemical structure
Properties
-
Chemical name
(3R)-3-(4-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
-
Molecular weight
306.37 -
Molecular formula
C17H18N6 -
PubChem identifier
25126798 -
Storage instructions
Shipped at room temperature. Store at -20°C. -
Solubility overview
Soluble in DMSO to 16 mM and in ethanol to 32 mM
-
Handling
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Toxic, refer to SDS for further information.
Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
-
SMILES
C1CCC(C1)[C@@H](CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3 -
Source
Synthetic
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
Datasheets and documents
-
SDS download
-
Datasheet download
References (2)
ab141356 has been referenced in 2 publications.
- Qian ZY et al. Ruxolitinib attenuates secondary injury after traumatic spinal cord injury. Neural Regen Res 17:2029-2035 (2022). PubMed: 35142693
- Tošic I et al. Lipidome-based Targeting of STAT3-driven Breast Cancer Cells Using Poly-l-glutamic Acid-coated Layer-by-Layer Nanoparticles. Mol Cancer Ther 20:726-738 (2021). PubMed: 33536189